Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3268)	12/9/1997 9:50:00 PM
From: John F Beule	Respond to of 6136

A solidarity fund?! Maybe when there is a silver bullet vaccine. As it stands, there are only methods to control the virus, not kill it. There needs to be a larger effort in letting the world know the implications and limitations of these drugs currently on the market. It's impossible for the majority of the population in these third world countries to get 3 square meals a day everyday. How in the world are patients going to be monitored (and kept) to staying on a drug regimen that, once broken, the virus mutates and a whole new drug regimen needs to be profiled. To make things even harder, patients are on it for life. If this was a perfect world, in the 3rd world countries this might work. Unfortunately, it's not, and because (IMO) lack of due diligence on the part of the general public, the pharmaceutical co's take the fall. Piot has a valid point, and he answers his own question. UNAIDS should focus on clearing the path (getting rid of lawyers' "teeth") to make "silver bullets" a viable consideration to all pharmaceutical co's.